CNS Pharmaceuticals Stock Price, News & Analysis

CNS Pharmaceuticals, a biopharmaceutical company focused on cancer treatments, will participate in a Virtual Investor Glioblastoma Multiforme (GBM) Spotlight event on April 14, 2022, at 11:30 AM ET. The event will feature CEO John Climaco and Key Opinion Leader Dr. Samuel A. Goldlust discussing CNS's innovative drug, Berubicin, aimed at treating recurrent GBM. Berubicin is the first anthracycline drug to potentially cross the blood-brain barrier, showcasing promising results in early trials for aggressive brain cancer.

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) has received the green light from the French ethics committee and the National Agency for the Safety of Medicines for its pivotal study of Berubicin, a treatment for recurrent glioblastoma multiforme (GBM). This approval opens doors to patient enrollment in France, a key step in advancing the trial. The study will involve 243 adults, with Overall Survival as the primary endpoint. Berubicin has also received Fast Track Designation and Orphan Drug Designation from the FDA, highlighting its potential as a groundbreaking therapy for GBM.

CNS Pharmaceuticals announced receiving regulatory approval from Swissmedic for its pivotal study of Berubicin, aimed at treating recurrent glioblastoma multiforme (GBM). The approval allows for patient enrollment in Switzerland, essential for advancing this promising treatment. The study will randomize approximately 243 patients to evaluate overall survival compared to lomustine, with a pre-planned futility analysis at 30-50% patient completion. Berubicin has gained Fast Track Designation and Orphan Drug Designation from the FDA, enhancing its development prospects.

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) announced CEO John Climaco's participation in the 2022 Virtual Growth Conference from March 28-30, 2022. Climaco will engage in a live fireside chat on March 30, 2022, at 2:30 PM ET, moderated by Maxim Group's Jason McCarthy. The conference covers diverse sectors and features presentations and Q&As with executives. CNS specializes in novel cancer treatments, including its lead drug candidate Berubicin, aimed at brain cancers. Interested attendees can register on M-Vest.

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) announced operational and clinical advancements regarding its lead product, Berubicin, in a recent shareholder video. CEO John Climaco expressed frustration with the company's share price fluctuations but emphasized strong patient enrollment in a pivotal study for glioblastoma treatment. Berubicin, a novel anthracycline designed to cross the blood-brain barrier, is currently undergoing trials at various clinical sites globally. The company continues discussions with the FDA to ensure trial advancements, aiming to generate long-term shareholder value.

CNS Pharmaceuticals reported financial results for the year ended December 31, 2021, highlighting a net loss of $14 million, up from $9.5 million in 2020. The increase is attributed to elevated personnel costs and activities for the clinical trial of Berubicin, which received Fast Track Designation and aims to treat recurrent Glioblastoma Multiforme (rGBM). The company also completed a $11.5 million private placement in January 2022 to support ongoing development. Key upcoming milestones include expanding clinical trials and filing an IND for WP1244/WP1874.

CNS Pharmaceuticals (NASDAQ: CNSP) announced participation in the Virtual Investor 2022 Top Picks Conference on January 26, 2022, at 11:00 AM ET. CEO John Climaco will present the company's advancements in treatments for brain and CNS cancers, featuring their lead drug candidate, Berubicin, which effectively crosses the blood-brain barrier. The event will include a corporate presentation and an interactive Q&A session, allowing live and pre-submitted questions from investors. A live webcast will be available, with a replay accessible for one year.

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) announced the closing of a private placement, raising approximately $11.5 million through the sale of 12,105,264 shares of common stock at $0.95 per share. The accompanying warrants have an exercise price of $0.82 and are valid for five years. The funds from this placement will support clinical trials and general corporate activities. CNS plans to file a registration statement with the SEC within 15 days to cover the resale of shares issued during this transaction.

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) announced that CEO John Climaco will present at the H.C. Wainwright BioConnect Conference from January 10-13, 2022. The presentation will be available via a video webcast starting January 10 at 7:00 AM ET. CNS Pharmaceuticals focuses on developing innovative treatments for brain and CNS cancers, including the lead drug candidate Berubicin, which targets glioblastoma multiforme.